Search Results

Execution layers are required to turn AI recommendations into governed action in regulated workflows.

A new report by Bryter released today reveals where pharma can lead as patients turn to (and question) AI tools for mental health.

As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: speeding drug development.

NEW YORK, April 02, 2024 (GLOBE NEWSWIRE) -- Intelligencia AI , a provider of AI-powered solutions that support data-driven decision-making in drug development, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,948,667 on April 2, 2024. The patent titled, “System and Interfaces for Processing and Interacting With Clinical Data,” pertains to the company’s novel techniques for training and leveraging a machine learning (ML) model to predict th

New “click-to-sequence” platform lets researchers buy AI-designed antibody sequences online, using an AI system that learns from real lab results

The agency’s sweeping rollout and staff challenge underscore rising momentum behind agentic AI: advanced, multiagent systems now fueling early pilots in medical writing, patient engagement and regulatory workflows across the industry.

Success demonstrates the power of EMMI, Terray’s proprietary AI platform integrated with its rapidly expanding 13B+ target-ligand binding database and highly automated lab

With new UK clinical trial rules landing in 2026, the EU Biotech Act on the horizon and China and Australia gaining ground, CROs are zeroing in on study timelines, AI/ML and data privacy as the industry’s next pressure points.

Leading healthcare technology company Intelligencia AI™ recently appointed pharmaceutical industry leader Névine Zariffa as its Scientific Advisory Board Chair. Formalizing the Scientific Advisory Board demonstrates the company’s investment in growth and signals the next chapter of maturity for the 2017 New York-founded company.

While the benefits of AI are clear, the amount data sets needed for effective AI integration is proving to be a challenge. This is particularly true for cell therapy companies as they are eagerly seeking ways to reduce development costs. Two experts at Charles River Laboratories provide insights by giving their takeaways from their own AI integrations.